Cramer’s lightning round: Anheuser Busch no longer looks attractive

Anheuser Busch Inbev NV: “No. I can’t. I can’t go Anheuser Busch because I’ve got to tell you something: I think the world has gotten away from traditional beer and that’s why I like the hedge bet that Constellation’s making, STZ, which I think is going to buy the rest of Canopy [Growth] at one point. STZ is the one if you want to go beer.”

CarMax, Inc.: “No. CarMax? We don’t want to be there. On the car situation, I remain a believer that the cars have peaked and we don’t want to touch anything involved in that sector.”

Exelon Corp.: “I like Exelon very much. I do believe, remember, that I think interest rates are going much higher and that’s why I like it.”

Fiat Chrysler Automobiles NV: “No. Because you just said it right – legendary CEO. He was the company. I’d wait to see who they get next. That man was bankable.”

AbbVie Inc.: “At $92 today, I saw it and I said, ‘You know, I should just go out and tell people to buy it,’ but I like Abbott Labs more because [of CEO] Miles White.”

TJX Companies Inc.: “TJX, $107 to $109. Probably goes to $115. The quarter was unbelievable. You know what? People aren’t going to stop buying it here. $111, $112 – take it.”

United Parcel Service, Inc.: “Buy it. Buy it. Just buy it. Just buy UPS. Something’s going on. UPS!”

Applied Materials, Inc.: “AMAT, $41 today. I saw it break to $40. I don’t even think it’s going to be able to hold $39. I think you’ve got to stay away from that. If you want to do it, then just go buy AMD and secondarily Nvidia after it’s down another 5 [basis points].”

Exelixis, Inc.: “I liked that for a long time. I was the only guy who liked it and now everybody likes it, so that makes me say don’t buy.”

Bank of America Corp.: “Bank of America at $31. It probably goes to $35, 36. I do like J.P. Morgan more at $114, though, or Citi at $71 – [Citi] sells at only 10 times earnings and [CEO Michael] Corbat’s doing a fantastic job.”

Nuance Communications Inc.: “No. I don’t care for it. Don’t go spec. We’ve got so many techs that are down. Let’s go high, high, high.”

Endo International PLC: “Endo Pharmaceuticals is really kind of a weird breakup story. I don’t know how much upside there really is. I’m going to take a pass on that and if we’re going to do pharma, by the way, we’re going to do Amgen, which is cheap.”

Source link

Products You May Like

Articles You May Like

Jaguar I-Pace electric SUV sweeps awards at New York auto show
Cramer Remix: Memo to President Trump
US manufacturing output unchanged in March
Unhappy with your tax return? How to prepare for 2019
BlackRock q1 earnings

Leave a Reply

Your email address will not be published. Required fields are marked *